Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 373.88B |
| Revenue (ttm) | 85.17B |
| Net Income (ttm) | 13.49B |
| Shares Out | n/a |
| EPS (ttm) | 5.55 |
| PE Ratio | 27.72 |
| Forward PE | n/a |
| Dividend | 4.62 (2.99%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 4,400 |
| Average Volume | 3,772 |
| Open | 151.78 |
| Previous Close | 152.50 |
| Day's Range | 151.36 - 154.98 |
| 52-Week Range | 132.78 - 154.98 |
| Beta | 0.51 |
| RSI | 70.71 |
| Earnings Date | Apr 15, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
JNJ met main goal in late-stage trial for ulcerative colitis treatment
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinical...
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinical...
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States.
Johnson & Johnson (JNJ) Completes Public Offerings of Notes
Johnson & Johnson (JNJ) Completes Public Offerings of Notes
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of thi...
BDA Promotes Sales Leader to Managing Director, EMEA
Stuart Shepherd Appointed to Drive Business Growth and Operational Alignment Across the Region WOODINVILLE, Wash., Feb. 19, 2025 /PRNewswire/ -- Bensussen Deutsch & Associates, LLC (BDA), the nation's...
Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value
Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value
Fast Money: CELH, SLV, EEM, JNJ
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
Fast Money: CELH, SLV, EEM, JNJ
The final trades of the day with CNBCs Dominic Chu and the Fast Money traders.
Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan
What J&J Is Trying to Achieve in Bankruptcy Court
Johnson & Johnson begins a two-week trial on Feb. 18 over its plan to end tens of thousands of lawsuits filed by women or their family members.
Nvidia surges: Healthcare sector struggles in mixed market
Nvidia surges: Healthcare sector struggles in mixed market The stock market presented a mixed bag today, highlighting remarkable gains in the semiconductor space led by Nvidia, while the healthcare se...
J&J begins crucial battle over $10 billion baby powder settlement
Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on i...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Johnson & Johnson to resume U.S. Varipulse cases after safety review
J&J resumes US rollout of Varipulse heart device after investigation
Johnson & Johnson said on Friday it has resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.
Dividend Roundup: Meta Platforms, Nike, Ford, Johnson & Johnson, and more
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
Johnson & Johnson Unveils Promising Data on Nipocalimab for Autoantibody Diseases
Johnson & Johnson Unveils Promising Data on Nipocalimab for Autoantibody Diseases
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
SPRING HOUSE, Pa., Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigatio...
J&J to discontinue E.coli vaccine candidate study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.
Class action targets ‘ineffective’ phenylephrine-based cold medicines
Law firm files action against Johnson & Johnson.